Brief: Apollomics Announces Efficacy Of Vebreltinib In Nsclc Patients With Metex14 Skipping Mutation Achieving An Overall Response Rate (Orr) Of 75%
23/10/2023 14:23
Oct 23 (Reuters) - Apollomics Inc APLM.O :
* APOLLOMICS ANNOUNCES EFFICACY OF VEBRELTINIB IN NSCLC
PATIENTS
WITH METEX14 SKIPPING MUTATION ACHIEVING AN OVERALL RESPONSE
RATE (ORR) OF 75%
Source text for Eikon: ID:nGNX5R1f8b
Further company coverage: APLM.O
((Reuters.Briefs@thomsonreuters.com;))